Silvia J Leon
Overview
Explore the profile of Silvia J Leon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dandeneau D, Leon S, Cameranesi M, Alexiuk M, Protudjer J, Protudjer J, et al.
Appl Physiol Nutr Metab
. 2025 Jan;
50:1-11.
PMID: 39854690
Risk factors contributing to cardiovascular diseases (CVD) can be addressed through behavior modification, including changes in diet and physical activity. In 2021, The Wellness Institute (WI), located at Seven Oaks...
2.
Alexiuk J, Harasemiw O, Vanderlinden J, Verrelli D, Tarca B, Collister D, et al.
Kidney360
. 2025 Jan;
PMID: 39854638
Background: Cognition is a research priority for people living with chronic kidney disease (CKD), but identification of critical research questions is lacking. This study aimed to determine which cognition-related research...
3.
Tangri N, Ferguson T, Bamforth R, Leon S, Arnott C, Mahaffey K, et al.
Diabetes Obes Metab
. 2024 May;
26(8):3371-3380.
PMID: 38807510
Aim: To validate the Klinrisk machine learning model for prediction of chronic kidney disease (CKD) progression in patients with type 2 diabetes in the pooled CANVAS/CREDENCE trials. Materials And Methods:...
4.
Tangri N, Ferguson T, Leon S, Anker S, Filippatos G, Pitt B, et al.
Clin Kidney J
. 2024 Apr;
17(4):sfae052.
PMID: 38650758
Background: Chronic kidney disease (CKD) affects >800 million individuals worldwide and is often underrecognized. Early detection, identification and treatment can delay disease progression. Klinrisk is a proprietary CKD progression risk...
5.
Pieroni D, Leon S, Krueger A, Burton L, Tremblay-Savard O, Tangri N, et al.
Can J Kidney Health Dis
. 2023 Nov;
10:20543581231212125.
PMID: 38020485
Background: During the 30-day period prior to initiating dialysis, there is a 10-fold rise in emergency department visits and hospitalizations related to kidney failure. Objective: The Virtual Ward Incorporating Electronic...
6.
Whitlock R, Leon S, Manacsa H, Askin N, Rigatto C, Fatoba S, et al.
Nephrol Dial Transplant
. 2023 Jun;
38(11):2503-2516.
PMID: 37309038
Background And Objectives: Dual renin-angiotensin-aldosterone system (RAAS) blockade involves dual therapy with a combination of angiotensin-converting enzyme inhibitors (ACEis), angiotensin-receptor blockers (ARBs), direct renin inhibitors (DRIs), or mineralocorticoid receptor antagonists...
7.
Wiens E, Leon S, Whitlock R, Tangri N, Shah A
Am J Cardiol
. 2023 May;
198:26-32.
PMID: 37196530
Dual antiplatelet therapy with acetylsalicylic acid and a P2Y12 inhibitor has become a mainstay of therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Although higher-potency P2Y12 inhibitors...
8.
Rossum K, Hancock E, Thompson S, Brar R, Riehl-Tonn V, Garcia E, et al.
Kidney Int Rep
. 2023 May;
8(5):1002-1012.
PMID: 37180520
Introduction: Intradialytic cycling is often performed during the first half of hemodialysis because of concerns regarding increased frequency of intradialytic hypotension (IDH) late in hemodialysis. This increases exercise program resource...
9.
Leon S, Carrero J
Curr Opin Nephrol Hypertens
. 2023 Feb;
32(3):290-296.
PMID: 36811640
Purpose Of Review: To discuss recent evidence on the benefits and harms of stopping therapy with renin-angiotensin-aldosterone system inhibitors (RAASi) after the occurrence of adverse events or in patients with...
10.